StreetInsider.com News Articles

Form 4 Inspire Medical Systems, For: Aug 31 Filed by: Kelly Jason P

Wed, 02 Sep 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20260902/27020731.html

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 09:15:00 -0400

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21^st Annual Healthcare Conference on Wednesday, September 9, 2026.

Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 09:15:00 -0400

Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the

Form 144 Inspire Medical Systems, Filed by: Rondoni John

Mon, 24 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260824/26968460.html

Form 144 Inspire Medical Systems, Filed by: Rondoni John

Mon, 24 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260824/26968460.html

Form SCHEDULE 13G/A Inspire Medical Systems, Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917380.html

Form SCHEDULE 13G/A Inspire Medical Systems, Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917380.html

Form SCHEDULE 13G Inspire Medical Systems, Filed by: AQR CAPITAL MANAGEMENT LLC

Wed, 12 Aug 2026 12:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26911312.html

Form SCHEDULE 13G Inspire Medical Systems, Filed by: AQR CAPITAL MANAGEMENT LLC

Wed, 12 Aug 2026 12:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26911312.html

Form 4 Inspire Medical Systems, For: Aug 07 Filed by: Kelly Jason P

Tue, 11 Aug 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260811/26907489.html

Form 4 Inspire Medical Systems, For: Aug 07 Filed by: Kelly Jason P

Tue, 11 Aug 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260811/26907489.html

Form 144 Inspire Medical Systems, Filed by: Kelly Jason P

Fri, 07 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260807/26891090.html

Form 144 Inspire Medical Systems, Filed by: Kelly Jason P

Fri, 07 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260807/26891090.html

Form 4 Inspire Medical Systems, For: Jul 31 Filed by: Mann Melissa

Tue, 04 Aug 2026 20:26:00 -0400

si-local-file:///var/storage/secattach/20260804/26868571.html

Form 4 Inspire Medical Systems, For: Jul 31 Filed by: Mann Melissa

Tue, 04 Aug 2026 20:26:00 -0400

si-local-file:///var/storage/secattach/20260804/26868571.html

Inspire Medical Systems (INSP) PT Raised to $75 at Stifel

Tue, 04 Aug 2026 10:00:01 -0400

(Updated - August 4, 2026 10:00 AM EDT)

Stifel analyst Jonathan Block raised the price target on Inspire Medical Systems (NYSE: INSP) to $75.00 (from $65.00) while maintaining a Buy rating.

The analyst commented, "The first step is to stop the bleeding, which Inspire accomplished this evening. After a handful of 2026 negative guidance revisions, Inspire reported 2Q26 revenue ahead of consensus and modestly increased the bottom-end of 2026 revenue guidance, while more meaningfully increasing EPS. The environment has been tumultuous over the past ~9 months, with what was anticipated to be a big reimbursement tailwind, turning to uncertainty, and then a

Inspire Medical Systems (INSP) PT Raised to $75 at Stifel

Tue, 04 Aug 2026 10:00:01 -0400

(Updated - August 4, 2026 10:00 AM EDT)

Stifel analyst Jonathan Block raised the price target on Inspire Medical Systems (NYSE: INSP) to $75.00 (from $65.00) while maintaining a Buy rating.

Inspire Medical Systems (INSP) PT Raised to $60 at Piper Sandler

Tue, 04 Aug 2026 08:58:29 -0400

(Updated - August 4, 2026 8:58 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $55.00) while maintaining a Neutral rating.

The analyst commented: "Q2 A Step In The Right Direction, But Still More Work To Do; INSP reported at Q2 beat with revenue of $200.6M vs. the Street's $195M forecast, while adj. EPS of $0.14 compared to the Street's -$0.25 bogey. Management increased its FY2026 guidance across-the-board after cutting guidance last quarter, including revenue of $835-875M (-8% to -4% y/y) from $825-875M (-10% to -4% y/y), adj. op margin of

Inspire Medical Systems (INSP) PT Raised to $60 at Piper Sandler

Tue, 04 Aug 2026 08:58:29 -0400

(Updated - August 4, 2026 8:58 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $55.00) while maintaining a Neutral rating.

KeyBanc Reiterates Sector Weight Rating on Inspire Medical Systems (INSP)

Tue, 04 Aug 2026 08:53:28 -0400

KeyBanc analyst Brett Fishbin reiterated a Sector Weight rating on Inspire Medical Systems (NYSE: INSP).

The analyst commented: "Maintain SW post 2Q. We believe investors will view 2Q earnings as directionally positive, given INSP appears to have found a floor around 2026 reimbursement uncertainty. More specifically: 1) revenue was modestly ahead of subdued expectations, as the impact from previously communicated headwinds was somewhat less impactful than estimated; 2) INSP increased its 2026 outlook for revenue and earnings, primarily to account for 2Q outperformance; and 3) INSP announced a strategic restructuring to support LT revenue growth. Raising estimates for results and guidance."

For

Inspire Medical Systems (INSP) PT Raised to $60 at RBC Capital

Tue, 04 Aug 2026 08:45:41 -0400

(Updated - August 4, 2026 8:45 AM EDT)

RBC Capital analyst Shagun Singh raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $45.00) while maintaining a Sector Perform rating.

The analyst commented: "Strategic Growth Plan is a Good Step, But Visibility Remains Limited; Our View: INSP delivered a Q2 beat/raise with revenue of $201MM (down 7.6% y/y) ahead of cons/$195MM and adj. OM of 1.6% vs. a guided operating loss, sending the stock up ~15% on growth plan and disciplined P&L management. INSP narrowed full-year coding impact ($120-130MM from $120-150MM), and announced growth reinvestment via Project Horizon that

Inspire Medical Systems (INSP) PT Raised to $60 at RBC Capital

Tue, 04 Aug 2026 08:45:41 -0400

(Updated - August 4, 2026 8:45 AM EDT)

RBC Capital analyst Shagun Singh raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $45.00) while maintaining a Sector Perform rating.

Inspire Medical Systems (INSP) PT Raised to $60 at JPMorgan

Tue, 04 Aug 2026 08:12:24 -0400

JPMorgan analyst Robbie Marcus raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $54.00) while maintaining a Neutral rating.

Inspire Medical Systems (INSP) PT Raised to $62 at Truist Securities

Tue, 04 Aug 2026 07:09:53 -0400

Truist Securities analyst Richard Newitter raised the price target on Inspire Medical Systems (NYSE: INSP) to $62.00 (from $54.00) while maintaining a Hold rating.

Oppenheimer 'Tactically' Upgrades Inspire Medical Systems (INSP) to Outperform 'Despite Noisy Fundamentals'

Tue, 04 Aug 2026 06:52:00 -0400

(Updated - August 4, 2026 6:52 AM EDT)

Oppenheimer analyst Suraj Kalia upgraded Inspire Medical Systems (NYSE: INSP) from Perform to Outperform with a price target of $85.00.

The analyst comments "INSP's 2Q revenues of $201M slightly outpaced our/consensus $195M/$195M estimates, driven by a surprise OUS contribution (distributor stocking unclear). Our anti-consensus thesis of limited HGNS TAM and mixed outcomes has played out, and we expect US reimbursement drama to continue. However, at these levels, there is "noisy" value to the story as an MSD-HSD grower; hence, we are upgrading the stock to OP/$85 PT. Our residual concerns: 1) Medicare billing for